Profit before payment of interest, taxes and amortization: ADC Therapeutics SA (ADCT)

ADC Therapeutics monetizes innovative antibody-drug conjugates, establishing premium pricing through its patents. The distribution of EBITDA across periods confirms the effectiveness of this strategy, where 0.00 serves as the current metric level. The forecast relies on an asset-light model with outsourced manufacturing and the high geopolitical resilience of the biomedical sector, which guarantees the stability of the company's operational activities.

ADC Therapeutics SA (ADCT) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/12/2026

ADC Therapeutics SA (ADCT) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart ADC Pharma|ADCT - Price Target Chart

- company stock exchange capitalization indicators:

Market Value ADC Therapeutics|ADCT - Total Company Value

- business book valuation details:

Net Asset Value per Share ADC Therapeutics|ADCT - Company Book Value|Market-to-Book Ratio adctherapeutics.com|ADCT - Company Total Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

ADCT - Net Income|Future Net Profit ADC Therapeutics|ADCT - P/E Multiple|Future Price to Earnings Multiple adctherapeutics.com|ADCT - PEG Multiple|Company Value to EBITDA ADC Therapeutics|ADCT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year ADC Therapeutics|ADCT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth adctherapeutics.com|ADCT - Earnings per share growth in current year|Net earnings per share change forecast for next year ADC Therapeutics

Summary company analytics:ADC Pharma - ADCT

Flagship merchandise of ADC Therapeutics SA

Professional capital evaluates ADC Therapeutics (ADCT) through the lens of its ability to commercialize a lymphoma drug amidst high R&D expenditure pressure. By analyzing absolute profit from core operations, the investor observes the daily net cash inflow from sales minus operating expenses, which allows for an objective assessment of risky cash flow volatility and real business efficiency.

Who ADC Therapeutics competes with

TG Pharma - Profit before payment of interest, taxes and amortization|ACLX - Profit before payment of interest, taxes and amortization|IRON: Profit before payment of interest, taxes and amortization|Syndax Pharmaceuticals, Inc. (SNDX) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kura Oncology Inc (KURA)|Profit before payment of interest, taxes and amortization Foghorn Therapeutics, Inc.|Profit before interest, taxes and amortization Vor Bio Inc. VOR|Operating profit EBITDA NKTX|coeptistx.com - Operating profit before amortization|Operating profit EBITDA ATNM (Actinium Pharmaceuticals, Inc.)|Operating profit EBITDA Estrella Immunopharma Inc ESLA|CASI Pharmaceuticals, Inc - Operating profit EBITDA|MRKR (Marker Therapeutics) - Operating profit before amortization|INAB: Operating profit EBITDA|Operating profit before deduction of amortization Eterna Therapeutics Inc.|Operating profit before deduction of amortization GTBP|APTO: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization BPTH (Bio-Path)|Company profit before taxes, interest and amortization MEIP|Operating profit EBITDA VINC (Vincerx Pharma)